SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (āSanaā), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
Related Questions
What is the expected impact on shortāterm liquidity and bidāask spread for SANA shares postāoffering?
What impact could the issuance of new common stock and warrants have on the company's earnings per share (EPS) and net tangible assets?
What is the pricing and exercise price of the preāfunded warrants and how does it compare to the current market price?
How much potential dilution could result if the underwritersā 30āday option is exercised?
Are there any antiādilution provisions in the preāfunded warrants that could affect future financing terms?
Could the increased float from this offering lead to higher volatility or altered price discovery dynamics?
Will there be a lockāup period for existing shareholders or insiders, and how might that affect future trading volumes?
How does this offering size and structure compare to recent capital raises by peer biotech companies?
What use of proceeds does Sana Biotechnology plan for the $75āÆmillion capital raise?
How might the marketās perception of Sanaās growth prospects change in response to this capital raise?